Skip to content
Friday, 20 November 2026
BREAKING
HEALTH

India Emerges as a Global Research Hub for Diabetes and Genetic Disorders, Says Minister Jitendra Singh

India is becoming a global center for diabetes and genetic research, with innovative health solutions, according to Minister Jitendra Singh.

New Delhi, November 20 (Daily Kiran) : Central Minister of State for Science and Technology, Dr. Jitendra Singh, announced on November 20 that India is rapidly emerging as a global research center for diabetes, genetic disorders, and next-generation health technologies. Speaking at the inauguration of RSSDI 2026 in Bengaluru, he highlighted that over a dozen diabetes-related research projects are currently underway under the Ministry of Science and Technology.

Dr. Singh emphasized that India’s vast population and genetic diversity provide a unique opportunity to develop health solutions that can benefit not only the country but the entire world. He identified the rising rates of obesity and diabetes among the youth as a serious challenge, stating that it is not just a medical issue but a national responsibility. He called for collaboration among society, government, educational institutions, and the healthcare sector to tackle these problems.

He noted significant changes in India’s science and health services over recent years. The country is now focusing on developing indigenous vaccines, treatment methods, antibiotics, and advanced health technologies, reducing its reliance on foreign solutions. Dr. Singh cited India’s DNA-based COVID-19 vaccine, homegrown antibiotics, genetic medicine research, biosimilar drugs, and the India Genome Study as examples of the nation’s contributions to global scientific research.

The minister pointed out that India’s research framework is adopting an innovation-driven approach to address complex health challenges and is continuously working on new medical technologies. The conference brought together leading diabetes specialists, physicians, researchers, educators, and health professionals from both India and abroad.

Dr. Singh also mentioned the growing focus on precision medicine and molecular-level treatments, which are opening new avenues for understanding and preventing type 2 diabetes and related metabolic disorders. Given the rising diabetes rates among young people, this research is becoming increasingly crucial.

He stressed the need for greater collaboration among government research institutions, private sector researchers, physicians, startups, and medical organizations, asserting that collective efforts could accelerate innovation in the health sector. Dr. Singh highlighted ongoing efforts to develop temperature-tolerant insulin, which would address storage and transportation challenges, especially in remote and rural areas.

Additionally, he noted that some Indian startups are researching oral insulin, emphasizing the vital role of institutional support in advancing such innovations. India has made significant strides in affordable diabetes treatment technologies, with the development of indigenous biosimilar products like liraglutide and insulin lispro, enhancing the availability of cost-effective and effective diabetes care.

Share